Kalaris Therapeutics Inc Stock Analysis & AI Score
Kalaris Therapeutics Inc (KLRS) has an ST Score of 54.3 (B-), driven by its Growth (A) and held back by its Momentum (D). Analysts rate it Buy with a $15.50 price target (+404.9% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Kalaris Therapeutics Inc (KLRS) has an ST Score of 54.3 (B-), driven by its Growth (A) and held back by its Momentum (D). Analysts rate it Buy with a $15.50 price target (+404.9% upside).
- Strongest
- GrowthA
- Weakest
- MomentumD
All factor grades
- GrowthA
- ForecastA
- Financial StrengthA-
- ValuationB
- ProfitabilityC
- MomentumD
- Piotroski0/9
Contact
KLRS stock: frequently asked questions
What is KLRS's ST Score?
Kalaris Therapeutics Inc (KLRS) has an ST Score of 54.3 (B-), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is KLRS a buy, hold, or sell?
Analysts rate KLRS a Buy, with a price target of $15.50 (+404.9% vs the current price). Our ST Score grades it B- (54.3/100). The ST Score is a data-driven signal, not a recommendation.
What are KLRS's factor grades?
Valuation B, Profitability C, Financial Strength A-, Momentum D, Growth A, Forecast A.
What is KLRS's valuation grade?
Kalaris Therapeutics Inc (KLRS) earns a valuation grade of B, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is KLRS's growth grade?
Kalaris Therapeutics Inc (KLRS) earns a growth grade of A, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is KLRS's profitability grade?
Kalaris Therapeutics Inc (KLRS) earns a profitability grade of C, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is KLRS's financial strength grade?
Kalaris Therapeutics Inc (KLRS) earns a financial strength grade of A-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for KLRS?
The average analyst price target for Kalaris Therapeutics Inc (KLRS) is $15.50 from 1 analysts, which is +404.9% versus the recent price of $3.07.
What is KLRS's Piotroski score?
Kalaris Therapeutics Inc (KLRS) has a Piotroski F-Score of 0 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.